AUSTRALIA'S CITY OF CULTURE, INVITES YOU TO
THE AUSTRALASIAN COLLEGE OF DERMATOLOGISTS

ASM48
ADELAIDE

48TH ANNUAL SCIENTIFIC MEETING
SATURDAY 16 MAY TO TUESDAY 19 MAY 2015

INCLUDES
AUSTRALIAN DERMATOLOGY NURSES’ ASSOCIATION
14TH NATIONAL CONFERENCE
SATURDAY 16 MAY AND SUNDAY 17 MAY 2015

AUSTRALASIAN SOCIETY OF COSMETIC DERMATOLOGISTS
2ND ANNUAL MEETING
MONDAY 18 MAY AND TUESDAY 19 MAY 2015
The 48th Annual Scientific Meeting of the Australasian College of Dermatologists will be held at the Adelaide Convention Centre (ACC), Adelaide, South Australia, from Saturday 16 May to Tuesday 19 May 2015.

FROM THE PRESIDENT

This brochure sets out the program and other information for the 48th Annual Scientific Meeting of the Australasian College of Dermatologists which will be held in Adelaide.

The convenors of the meeting are Dr Karen Koh, Dr Priya Selva-Nayagam and Dr Sachin Vaidya. The South Australian Faculty welcomes Fellows, trainees, students and other medical practitioners to the meeting.

It also includes the programs for the meetings of the Australian Dermatology Nurses’ Association and the Australasian Society of Cosmetic Dermatologists. You can register for any or all of the three meetings on the single registration form which accompanies this brochure. Online registration if eligible, for all three meetings is also available through the College website: www.dermcoll.edu.au.

The Annual Scientific Meeting program incorporates major changes to the meeting previously adopted by the College. These include that the meeting is now four days duration, commencing on Saturday and finishing on Tuesday; that there will be concurrent sessions including incorporating the Australasian Society of Cosmetic Dermatologists and overlapping with both the Australian Dermatology Nurses Associations’ meeting and the meeting of the Australasian Society for Dermatologic Research. This will offer delegates a variety of choices.

I am pleased that the meeting will be strongly supported by the pharmaceutical and allied health industries, both as sponsors and as trade exhibitors.

Full details of all aspects of the meeting will be announced in the final program available both upon arrival at the meeting and prior, on our website, www.dermcoll.edu.au.

I hope you will join us in what promises to be one of our most exciting meetings. I look forward to catching up with you in Adelaide.

A/Prof. Stephen Shumack, OAM, FACD, FAICD
Adelaide has been voted Australia’s most liveable city and one of Lonely Planet’s top 10 must-visit cities for 2014. It is undoubtedly the cultural capital of Australia. With its elegant, historic buildings, its wide boulevards, its easily manageable grid street pattern, its Victorian-era parks and monuments, Adelaide is the jewel in the Australian crown.

The city is characterised by elegant shopping arcades, wine bars and coffee shops, some 700 restaurants, pubs, cafes and eat streets and many art galleries and museums.

South Australia itself is home to stunning beaches and award-winning wine events and festivals. Adelaide is the gateway to the Barossa, the Adelaide Hills, Flinders Ranges, the outback and Kangaroo Island. The South Australian coastline is more than 3,800 km long and is punctuated by towns, beaches, cliffs and jetties. Many coastal regions offer fantastic fishing, boating and surfing, as well as quality wines and fresh produce, including local seafood.

North Terrace is Adelaide’s cultural boulevard, with its many art and cultural sites, including the Art Gallery of South Australia, the Migration Museum and the South Australian Museum. It is also the site of the re-developed Adelaide Convention Centre, the venue for the Annual Scientific Meeting. Immediately adjoining, are the new South Australian Health and Medical Research Institute (SAHMRI) and the re-located Royal Adelaide Hospital.

For more information, please visit www.southaustralia.com/regions/adelaide-city-visitor-information-centres.aspx.
Adelaide Convention Centre
North Terrace
ADELAIDE SA 5000
Australia
T +61 8 8212 4099
F +61 8 8212 5101

The ACC has undergone a major re-development and extensions. Adelaide now has the newest and most modern convention facilities in Australasia. The ACC now occupies a much greater part of North Terrace, stretching from the Adelaide Festival Centre to Morphett Street. Access from Morphett Street is now the principal entry point for the venue.

The new ACC extensions include plenary halls, meeting rooms and a ballroom. These will form the venue for the College meeting.

The plenary sessions will be held in the Hall L. Concurrent sessions will be held in Hall M. The Registration Desk will be located in the Hall M Foyer. The Conference organiser’s office and secretariat will be in the Hall H Office. The trade exhibition will be in Hall H.

Morning and afternoon teas and lunches will be served in the trade exhibition.
The visiting speakers will be:

**Marcus Maurer, MD**

Marcus Maurer is Professor of Dermatology and Allergy and Director of Research at the Department of Dermatology and Allergy, Allergie-Centrum-Charité of the Charité - Universitätsmedizin in Berlin. He is also Head of the Specialty Clinics for Urticaria, Mastocytosis, Pruritus, Autoinflammatory Disorders and Angioedema and the Dermatological Allergology Laboratory. His areas of interest include the characterisation of physiological functions of mast cells, neuroimmunology, inflammation, innate immunity, tolerance and pathogenesis and treatment of urticaria, mastocytosis, hereditary angioedema (HAE) and autoinflammatory diseases. Professor Maurer has authored more than 290 publications in peer-reviewed journals. He currently serves as a member of the following Editorial Boards: Advances in Dermatology and Allergology, International Archives of Allergy and Immunology, Allergo Journal, Allergy, Experimental Dermatology and the WAO Journal.

Professor Maurer’s participation in the meeting is assisted by an unconditional grant to College by **Novartis**

**Albert C. Yan, MD**

Dr Yan currently serves as the Chief of the Section of Paediatric Dermatology at the Children’s Hospital of Philadelphia where he is Professor of Paediatrics and Dermatology at the Perelman School of Medicine at the University of Pennsylvania. He received his AB in Philosophy from Princeton University and his MD from the University of Pennsylvania. He is a past President of the Society for Paediatric Dermatology, and is the incoming Chair of the AAP Section on Dermatology Executive Committee. Dr Yan is also the co-chief Editor of the 3rd edition of Harper’s Textbook of Paediatric Dermatology. His areas of interest include acne, atopic dermatitis, haemangiomas and vascular anomalies, skin infections as well as paediatric dermatology education and workforce issues.

**Amit G. Pandya, MD**

Dr Pandya is a Professor in the Department of Dermatology at the University of Texas Southwestern Medical Center in Dallas, Texas, USA. He earned his Doctor of Medicine degree from UT Southwestern Medical School and completed residencies in internal medicine at Presbyterian Hospital of Dallas and in dermatology at UT Southwestern Medical Center. Dr Pandya has a special interest in vitiligo, melasma and other pigmentary disorders. His ongoing clinical research is focused on the etiology, epidemiology, measurement, quality of life, diagnosis and treatment of these cutaneous disorders. Dr Pandya is also the co-chief Editor of the 3rd edition of Harper’s Textbook of Paediatric Dermatology. His areas of interest include acne, atopic dermatitis, haemangiomas and vascular anomalies, skin infections as well as paediatric dermatology education and workforce issues.

**John G. Albertini, MD**

Dr Albertini currently serves as President of the American College of Mohs Surgery (ACMS), founded in 1967 by Dr Frederic Mohs for fellowship-trained skin cancer and reconstructive surgeons. He attended medical school at The University of Chicago. He then trained at UC San Francisco in Internal Medicine (internship) and Geisinger Medical Center in Dermatology and Mohs Surgery (residency and fellowship). After active duty Air Force military service in San Antonio, Texas as Chief of Mohs Surgery, he entered private practice at The Skin Surgery Center in North Carolina where he has been recognised annually as a ‘Best Doctor’ since 2005. He has presented over 50 local, regional and national lectures and has published over 40 scientific articles and book chapters. Dr Albertini has served as President of the North Carolina Dermatologic Association (2009) and as Assistant Editor of the Journal Dermatologic Surgery (2009-2015). He was invited to be Guest Editor for the Special Issue on Advanced Reconstruction published in 2014. Dr Albertini also served as Fellowship Director of an ACGME approved training program in Mohs surgery and procedural dermatology (2007-2013). He currently collaborates with faculty and helps trains residents in his role of Associate Professor (Volunteer) at Wake Forest University Department of Plastic and Reconstructive Surgery.

**Christoph Martschin, MD**

Dr Martschin is a senior consultant dermatologist in medical and aesthetic dermatology in Sweden. He was educated at Innsbruck Medical University, Austria and undertook training in aesthetic dermatology in the USA, UK, Germany and Sweden. In 2012-13 he worked at Karolinska University Hospital in Stockholm before entering private practice. He lectures and trains in injection technique with focus on facial volume restoration, lip augmentation, skin boosters, facial anatomy and prevention/treatment of side-effects. He serves on advisory boards for Botulinum toxin and injection strategy.

**Torsten Walker, MD**

Following his education at the Universities of Graz, Heidelberg and New York, Dr Walker specialised as a dermatologist in Ludwigshafen and Amberg in Germany. His doctorate thesis was about penicillin allergy and diagnostic problems. Following board certification he specialised in aesthetic treatments. From 2005 to 2012 he was senior physician in the Department of Dermatology in Wiesbaden. He runs his own private clinic in Ludwigshafen with an aesthetic focus. He is experienced in Botulinum toxin A treatments, fillers and liposuction and especially in deep chemical peel with Phenol solution. Dr Walker is a member of the German Botulinum Toxin Society, an honorary member of the Jordanian Dermatologic Society and a founding member of the International Peeling Society.

Dr Walker’s participation in the meeting is assisted by an unconditional grant to College by **Weare Aesthetics**
SPONSORED SPEAKERS

Sponsored speakers will participate in sponsored symposia or breakfast sessions, and possibly also in the main program. They include:

**Dr Jeremy B. Green**

Dr Green is a fellowship-trained, board-certified, cosmetic dermatologist who completed his medical education at the Northwestern University Feinberg School of Medicine and the University of Miami Miller School of Medicine where he graduated with Alpha Omega Alpha (AOA) honours. He trained at the University of Miami Department of Dermatology and Cutaneous Surgery where he served as its chief resident. Dr Green completed advanced fellowship training in laser and cosmetic surgery at SkinCare Physicians in Boston, Massachusetts with clinical faculty from the Harvard and Yale Departments of Dermatology. Dr Green has authored numerous peer-reviewed publications and lectures, both nationally and internationally on cosmetic dermatology and laser surgery. He has presented at the annual meetings of the American Academy of Dermatology, the American Society for Laser Medicine and Surgery and the American Society for Dermatologic Surgery, among others. Dr Green is also a Voluntary Assistant Professor at the University of Miami Department of Dermatology where he provides patient care at Jackson Memorial Hospital and participates in resident education. Dr Green’s participation is made possible by the generous support of **CUTERA**

**Professor Thomas Luger**

Professor Luger is director and chairman of the Department of Dermatology at the Westfälische Wilhelms-Universität in Münster, Germany and head of the Ludwig Boltzmann Institute for Cell Biology and Immunology at the University. He has been Dean of the University’s Medical Faculty; and General Secretary and then President of the German Dermatological Society. His special field of interest is atopic dermatitis. Professor Luger’s participation is made possible by the generous support of **LA ROCHE-POSAY**

**Dr Emil Tanghetti**

Dr Tanghetti was born and raised in Sacramento. He attended the University of California Davis where he excelled in his studies and received early admission to USCLA School of Medicine after only three years of undergraduate studies. Upon completing his medical studies and a one year pathology fellowship, Dr Tanghetti graduated first in his class and received the Dean Warren Medal for Academic Excellence. After finishing residencies in internal medicine at Stanford University and dermatology at Harvard School of Medicine, he completed a photo-medicine fellowship at the Wellman Laboratories at the Massachusetts General Hospital. Dr Tanghetti is a board-certified dermatologist and a Fellow of the American Academy of Dermatology and the American Society for Laser Medicine and Surgery. He is currently listed in the “Best Doctors in America Pacific Region” and recognised as “Top Doc” by his peers in Sacramento Magazine. Dr Tanghetti has received the “Hero in Health Care” award for his volunteer work in removing tattoos for the California Youth Authority. Dr Tanghetti has been active in clinical studies for over a decade. Dr Tanghetti’s participation is made possible by the generous support of **CYNOSURE**

**Professor Eggert Stockfeth**

Professor Stockfeth is Director of the Skin Cancer Center Charité, Berlin. He gained his medical degree in 1991 from the University of Hamburg and since then has held positions at a number of universities and institutions both in Germany (amongst others at the German Cancer Research Center, Heidelberg) and the USA. He joined the University of Kiel in 1996 and in 1999 he was made Consultant of Dermatology, Venereology and Allergology. In 2001 he became University Professor at Charité – University Medical Center Berlin. Since 2004 he is the Head of the Skin Cancer Center Charité and since 2009 he is the Vice-Chairman of the Department of Dermatology, Venereology and Allergy. He is a member of a number of professional associations including the Berlin Society of Dermatology, the German Society of Dermatology, the Hamburg Dermatology Association, the German Cancer Association, the German Dermatology Association, the European Academy of Dermatology and Venereology and the European Dermatology Forum. He is also the former European President of Skin Care in Organ Transplant Patients Network (SCOPE). In 2008 he was one of the founders of the European Skin Cancer Foundation, which aims to assist in developing and providing standardised treatments on a European level.

His research on dermatology, oncology and particularly skin cancer, has been extensively published in peer-reviewed journals. He acts as referee for many different journals including **Journal of Investigative Dermatology** and **The Lancet**. His interests include: oncology, HPV-associated skin and mucosal skin tumours, skin tumours in organ transplant patients, general dermatology, apoptosis regulation, skin carcinogenesis, Immunology, tumourimmunology, molecular biology of skin tumours (melanoma, cutaneous lymphoma, cutaneous squamous cell carcinoma).

Dr Stockfeth’s participation in the meeting is made possible by the generous support of **MENARINI**
SPECIAL EVENTS

The following special events will be held in association with the meeting:

PATCH TEST TRAINING DAY
University of South Australia, City West Campus, Lecture Theatre HH3-09, Adelaide
Friday 15 May 2015
For more information, visit https://www.skincancer.asn.au/events/12/2015-patch-test-training-day.
If you have any enquiries, please contact Amanda Palmer telephone: 03 9623 942 or email apalmer@occderm.asn.au or A/Prof. Rosemary Nixon email: rnixon@occderm.asn.au.

AUSTRALASIAN SOCIETY FOR DERMATOLOGY RESEARCH
Stamford Plaza Adelaide Hotel
Friday 15 May and Saturday 16 May 2015
Convenors: A/Prof. Nikolas Hass and A/Prof. Helmut Schaider.

AUSTRALIAN DERMATOLOGY NURSES’ ASSOCIATION 14TH ANNUAL NATIONAL CONFERENCE
Adelaide Convention Centre
Saturday 16 May and Sunday 17 May 2015
For more details contact Australian Dermatology Nurses’ Association Secretary, Lynne Anderson, email: secretary@adna.org.au

AUSTRALASIAN SOCIETY OF COSMETIC DERMATOLOGISTS 2ND ANNUAL MEETING
Adelaide Convention Centre
Monday 18 May and Tuesday 19 May 2015
For more information, contact A/Prof G Goodman email: gg@div.net.au.
REGISTRATION
The Registration Desk will be located in the Hall M Foyer. The conference organiser’s office and the College secretariat will be in the Hall H Office. The registration desk will open on Saturday 16 May from 0800 and throughout the meeting. The College secretariat office will be open from 1000 to 1600 daily.

MEET THE ACD STAFF!
For the first time, College will have its own stand in the trade exhibition, manned by members of the College staff.
Come and meet us and find out what we can do for you. Pick up some leaflets and other freebies; find out about the website; check your CPD.
We are located just to the left, inside the main entrance of the trade exhibition.

TRADE EXHIBITION
The trade exhibition will be in Hall H. It will be open on the following days:
- Sunday 17 May from 1000 to 1600 (1245 official opening)
- Monday 18 May from 1000 to 1600
- Tuesday 19 May from 1000 to 1500
The morning and afternoon tea breaks will be for half an hour. The lunch break will normally be one hour, except on Monday 18 May and Tuesday 19 May 2015 when it will be longer.

APP
College is offering a free downloadable web-based app for the Annual Scientific Meeting. It will include information about the scientific program, social program, accommodation, etc. It will also be used for responder sessions during the meeting. The app can be used on most iPhones, notebooks and laptops.
**MENARINI SPONSORED BREAKFAST: A MASTERCLASS WITH PROF. EGGERT STOCKFLETH: EVIDENCE-BASED MANAGEMENT OF FIELD CANCERISATION**

Speaker: Prof. Eggert Stockfleth

---

**LA ROCHE-POSAY SPONSORED SYMPOSIUM: TARGETING THE HUMAN SKIN MICROBIOME IN PATIENTS WITH ATOPIC DERMATITIS**

Speaker: Prof. T. Luger

In patients with atopic dermatitis, a marked change in the skin microbiome diversity has been shown as a function of the disease severity. Exploration of the skin microbiome enables entirely new approaches for the treatment of infectious and inflammatory skin diseases.
The scientific sessions of the meeting will be held in Hall K.

**Saturday 16 May 2015**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>0800-</td>
<td>Registration open</td>
</tr>
<tr>
<td>0900-1000</td>
<td>Keynote Speaker: RN S. Lawton, OBE My dermatology journey from RN to OBE</td>
</tr>
<tr>
<td>1000-1030</td>
<td>Dr B. De’Ambrosis PNI and other nasties</td>
</tr>
<tr>
<td>1030-1100</td>
<td>Morning tea and networking</td>
</tr>
<tr>
<td>1100-1130</td>
<td>Dr K. Newland Cutaneous Lymphoma</td>
</tr>
<tr>
<td>1130-1200</td>
<td>Dr Y-C. Lee TBC – possibly anti-wrinkle injections and/or hyperhidrosis</td>
</tr>
<tr>
<td>1200-1230</td>
<td>State Education Day brainstorming</td>
</tr>
<tr>
<td>1230-1330</td>
<td>Lunch and networking</td>
</tr>
<tr>
<td>1330-1400</td>
<td>P. Faga, RN Anaphylaxis</td>
</tr>
<tr>
<td>1400-1430</td>
<td>Annual General Meeting</td>
</tr>
<tr>
<td>1430-1500</td>
<td>Afternoon tea and networking</td>
</tr>
<tr>
<td>1500-1530</td>
<td>Dr P. Artemi Surgical treatment of vitiligo</td>
</tr>
<tr>
<td>1530-1600</td>
<td>Dr T. Artemi Pharmacology in dermatology</td>
</tr>
<tr>
<td>1600-1630</td>
<td>Dr E. Ryan Talk on dermatology conditions common to the outback</td>
</tr>
</tbody>
</table>

**Proposed CPD points:** 5.5 hours

**Social Program**

Ego Nurses’ Dinner
National Wine Centre, Corner Botanic Road and Hackney Road, Adelaide
(ADNA members only, numbers limited)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
</table>
| 0730-0830  | BREAKFAST SESSIONS                                                      | NOVARTIS SPONSORED BREAKFAST: A NEW ERA FOR PSORIASIS PATIENTS: IL-17 INHIBITION
A/Prof. P. Foley  
Welcome and introduction
Dr L. Spelman  
IL-17 inhibition – the evidence
Dr J. Sullivan  
IL-17 inhibition – the patient
Q&A Panel Discussion  |
| 0730-0830  | JANSSEN SPONSORED BREAKFAST: TREATING THE FULL SPECTRUM: UNMET NEEDS IN PSORIASIS  |
| 0845-0850  | OFFICIAL OPENING BY A/PROF. S. SHUMACK, OAM, PRESIDENT, AUSTRALASIAN COLLEGE OF DERMATOLOGISTS  |
| 0850-1045  | PLENARY SESSION 1                                                      | Chair: A/Prof. S. Shumack  
Prof. M. Maurer  
Problems and solutions in the management of chronic urticaria  
Prof. A. Pandya  
Melasma: Differential diagnosis and pathogenesis  
Prof. A.Yan  
Preadolescent acne: The argument for early treatment  
Prof. J. Albertini  
Surgical pearls  |
| 1115-1245  | CONCURRENT SESSION 2A: MELANOMA SYMPOSIUM                                | Chair: Dr C. Reid  
Dr G. Carlos  
Reflectance confocal microscopy as a diagnostic aid in determined invasion in lentigo maligna clinical presentations  
Dr D. Deshpande  
Topical and intralesional therapies for loco-regional metastasis of cutaneous melanoma  
A/Prof. N. Haass  
Making stressed melanoma self-destruct  
Dr K. Crotty  
Be aware of the BAPoma  
Dr M. Brown  
Adjuvant treatment of melanoma  |
| 1115-1245  | CONCURRENT SESSION 2B: PAEDIATRICDERMATOLOGY SYMPOSIUM                  | Chair: Dr L. Warren  
Dr C. Barnett  
An update on genetic testing for the dermatologist  
Dr G. Harvey  
Genetics of a rare entity  
Dr J. Kerns  
Bullous pemphigoid in infants – characteristics, diagnosis and treatment  
Dr C. Chaptini  
Prevalence of methicillin-resistant Staphylococcus aureus in children with atopic dermatitis: A longitudinal study  
Dr S. Smith  
Assessment of pharmacists’ knowledge about use of topical corticosteroids in atopic dermatitis: Pre and post continuing professional development education  
Dr E. Mooney  
Adverse effects of topical corticosteroids in paediatric eczema: Australian consensus statement  
Dr S. Strathie  
SCALP syndrome: A rare clinical entity  
Dr C. Zhao  
Neonatal autoimmune blistering disease: A systematic review of the literature  |
### 1345-1515  
**CONCURRENT SESSION 3B: LASER SYMPOSIUM**  
Chair: Dr K. Koh

<table>
<thead>
<tr>
<th>Participant</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr D. Lim</td>
<td>High density 1927 thulium laser for actinic keratoses – is this the ideal field treatment?</td>
</tr>
<tr>
<td>Dr C. Robb</td>
<td>A novel hybrid ablative and non-ablative fractional resurfacing treatment for clinical efficacy with enhanced patient experience</td>
</tr>
<tr>
<td>Dr M. Rodrigues</td>
<td>Medication-induced pigmentation: A novel treatment for an age-old problem</td>
</tr>
<tr>
<td>Dr E. Tanghetti</td>
<td>Picosecond lasers</td>
</tr>
</tbody>
</table>

### 1545-1715  
**CONCURRENT SESSION 4A: NON-MELANOMA SKIN CANCER SYMPOSIUM**  
Chair: Dr W. Weightman

<table>
<thead>
<tr>
<th>Participant</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr R. Carroll</td>
<td>Immune phenotype and function: Management of immunosuppression in high risk SCC in renal transplant recipients</td>
</tr>
<tr>
<td>Dr J. Albertini</td>
<td>Non-melanoma skin cancer – lessons I have learned</td>
</tr>
<tr>
<td>Dr M. Cho</td>
<td>Scalp basal cell carcinoma: A review of 2202 cases</td>
</tr>
<tr>
<td>Dr A. Gupta</td>
<td>Management of squamous cell and basal cell carcinomas of the head and neck with perineural invasion</td>
</tr>
<tr>
<td>Dr J. Ma</td>
<td>In-transit squamous cell carcinomas: An Australian case series</td>
</tr>
</tbody>
</table>

### 1545-1715  
**CONCURRENT SESSION 4B: PIGMENTARY DISEASES SYMPOSIUM**  
Chair: Dr S. Vaidya

<table>
<thead>
<tr>
<th>Participant</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr S. Vaishampayan</td>
<td>Common and uncommon dermatoses in darker skin</td>
</tr>
<tr>
<td>Dr M. Rodrigues</td>
<td>Vitiligo: An approach to treatment</td>
</tr>
<tr>
<td>Dr P. Artemi</td>
<td>New surgical treatments for vitiligo</td>
</tr>
<tr>
<td>Dr S. Vaidya</td>
<td>Approach to hypopigmentation or depigmentation in children</td>
</tr>
<tr>
<td>Prof. A. Pandya</td>
<td>Management of post inflammatory hyperpigmentation</td>
</tr>
<tr>
<td>Dr A. Lim</td>
<td>Laser treatments in patients of darker skin types</td>
</tr>
</tbody>
</table>

### Questions

---

**GRADUATION ORATION AND CONFERRING OF DIPLOMAS AND AWARDS, ADELAIDE CONVENTION CENTRE**

John Reid Orator: Dr Peter Goldsworthy, AM  
Australian writer and medical practitioner
Sunday 17 May 2015

0730-0830  Janssen-Cilag Pharmaceuticals
Sponsored Breakfast: Biologics
CPD issued separately by Janssen-Cilag Pty Ltd

1000-1030  A/Prof. P. Fernandez-Peñas
How light is used in dermatology

1030–1030  S. Temby, RN
CPD requirements and how to present for auditing

1030-1100  Morning tea in ACD Trade Exhibition

1100-1130  Dr S. Eisman
Pigmented lesions

1130–1200  Dr L. Young
Topic: TBC

1200-1300  Lunch in ACD Trade Exhibition

1300–1330  G. Savoulian, RN
Treatment for chronic eczema from a nurse’s perspective

1330-1400  Dr A. Rudd
Topic: TBC

1400-1430  Dr G. Marshman
Dermatologic challenges in West Timor

1430-1445  A. Palmer, RN
Contact Allergan Bank

1445-1500  E. Senior, RN
Wound care case discussions

1500  S. Temby, President, ADNA
Close of conference

1500-  Afternoon tea in ACD Trade Exhibition

Proposed CPD points:  4.0 hours
0730-0830  LILY AUSTRALIA SPONSORED BREAKFAST: THE GREAT DEBATE: GOALS OF TREATMENT FOR SEVERE PSORIASIS – DO WE NEED TO REDEFINE THEM?
Chairs: A/Prof. P. Foley and Dr W. Weightman

0730-0830  LEO PHARMA SPONSORED BREAKFAST: OPTIMISING PATIENT OUTCOMES WITH PICATO® GEL: HOW FAR CAN IT GO?
Chair: Dr S. Smith
An interactive session on improving patient satisfaction within the clinic setting.

0845-1030  PLENARY SESSION 2
Chair: Dr J. Menz
Prof. M. Maurer  Chronic pruritus – what’s new in the aetiology, diagnostic work up and treatment?
Prof. A. Pandya  Management of melasma
Prof. M. Maurer  Innate immunity and autoinflammation – What do we need to know as dermatologists?

1100-1230  VIRTUAL CLINICAL MEETING
Chairs: Dr E. Ryan and Dr R. Manifold
A variety of interesting clinical cases will be presented for diagnosis and discussion of management

1400-1500  CONCURRENT SESSION 5A: GENITAL DERMATOLOGY SYMPOSIUM
Chair: Dr P. Selva-Nayagam
A/Prof. G. Fischer  Long term management of adult vulval lichen sclerosus: A prospective cohort study of 507 women
Dr A. Lee  Pre-pubertal onset vulval lichen sclerosus: The importance of maintenance therapy in long-term outcomes
Dr S. Strathie Page  Plasma cell vulvitis: Presentation of a case
Dr P. Selva-Nayagam  Plasma cell vulvitis: Is it one disease?
Dr S. Ball  On your bike! – when cycling is not always good for you
Dr D. Vekic  Phenotypic variations in hidradenitis suppurativa imply heterogeneous pathogenic pathways with potential adjuvant therapeutic targets

1400-1500  CONCURRENT SESSION 5A: FREE PAPERS SESSION
Chair: Dr K. Newland
Dr A. Chong  Dermatology teaching in Australian medical schools: Preliminary survey results
Dr J. Kerns  Multicentric reticulohistiocytosis: Rituximab as an alternative to established therapy regimens
Dr A. Sahebian  A review on dermatological side effects of current treatment regimens in lung transplant recipients
Dr C. de Belilovsky  E.V.E.I.L.S PROGRAM: Raman-spectroscopic electron and genomic characterization of newborn and children skin physiology
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 1530-1700 | ANNUAL GENERAL MEETING  
For Fellows and Associate Members of College only. |
| 1700-1800 | Cynosure Sponsored Symposium: Picosure - Past, Present and Future  
Speaker: Dr E. Tanghetti |
| 1700-1830 | Celgene Sponsored Symposium: Understanding Unmet Needs in Psoriasis, Psoriatic Arthritis and Small Molecule Oral Treatment Options  
Chair: A/Prof. P. Foley  
Speaker: A/Prof. P. Nash, Coast Joint Care (QLD)  
Session objectives:  
- Understand unmet physician and patient needs in psoriasis and psoriatic arthritis  
- Understand the pathophysiology and mechanisms of disease of psoriasis and psoriatic arthritis  
- Review the efficacy and safety for small molecule oral therapies for adults with moderate to severe plaque psoriasis  
- Identify distinctive features of psoriatic arthritis and implications for clinical management |
| 1700   | Arrival canapés and registration |
| 1730   | A/Prof. P. Foley  
Introduction and program objectives |
| 1735   | A/Prof. P. Foley  
Physician and patient unmet needs in psoriasis and psoriatic arthritis |
| 1740   | A/Prof. P. Nash  
Intracellular cytokine signaling pathways: A rational target in psoriasis and psoriatic arthritis |
| 1805   | A/Prof. P. Foley  
Small molecule oral therapies for psoriasis |
| 1820   | A/Prof. P. Foley and A/Prof. P. Nash  
Questions |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
</table>
| 1000–1045  | **SESSION 1: HOW TO START A COSMETIC PRACTICE AND HOW TO APPROACH A COSMETIC PATIENT**  
Dr B. Welsh/  
Dr B.Pruim  
Dr J. Green  
Panel discussion |
| 1045-1130  | **SESSION 2: APPROACH TO THE PATIENT: UNDERSTANDING AND ASSESSMENT OF THE COSMETIC PATIENT**  
Dr C. Martschin  
A/Prof. G. Goodman  
Questions and answers |
| 1130–1200  | **SESSION 3: ANATOMY OF THE FACE AND NECK: FACIAL ANATOMY FOR INJECTIONS AND FIELD BLOCKS, LOCAL ANAESTHESIA AND DANGER AREAS**  
Dr C. Martschin  
Panel |
| 1200-1300  | **SESSION 4: LASERS – HOW TO INTRODUCE TO YOUR PRACTICE**  
Chairs: Dr R. Rosen and Dr S. Manoharan  
TBC  
Dr D. Lim/  
Dr A. Lim  
Dr E. Tanghetti  
Tricks to enhance efficacy when treating vascular lesions and two wavelength devices 595/1064 – when to use and why |
| 1300-1400  | **LUNCH** |
| 1400–1430  | **SESSION 5: LASERS AND SUN DAMAGE**  
Chairs: Dr A. Sheridan and Dr S.W. Lim  
Dr E. Tanghetti  
Dr J. Green  
Questions |
| 1430-1530  | **SESSION 6: SPEED DATING WITH TRADE**  
10 minute trade talks in exhibition area |
| 1700-1830  | **SESSION 7: INJECTING DUMMY SESSION**  
Galderma team to conduct injecting dummy session with consultants and teams of registrars (Dr C. Martschin and local faculty). |
0730-0830  CUTERA AUSTRALIA PTY LTD SPONSORED BREAKFAST: THE LASER DERMATOLOGY EXPERIENCE USING PICO, NANO AND MILLI SECOND TECHNOLOGY IN CONJUNCTION WITH 532NM AND 1064NM WAVELENGTHS
Speaker: Dr J.B. Greene, MD
Dr Jeremy Green will present two of the most popular wavelengths in dermatology, 532nm KTP and 1064nm Nd:YAG for treatment of tattoos, pigmented lesions and vascular conditions. Dr Green will introduce Cutera’s Enlighten dual wavelength laser with the ability to produce pico second and nano second pulse durations in a single system. Dr Green will also present on the variety of conditions that can be treated with the new gold standard for vascular lesions, Cutera’s Excel V.

0730-0830  GALDERMA SPONSORED BREAKFAST: FROM LAMP TO LIGHT: HOW TO PERFORM DAYLIGHT ACTIVATED PDT
Chair: Dr L. Spelman

0845-1015  CONCURRENT SESSION 6A: GLOBAL DERMATOLOGY SYMPOSIUM
Chair: Dr T. O’Brien
Dr T. O’Brien  History of the International Dermatology Outreach Committee
Dr C. Grills/ India
Dr A. Howard  Out of Africa
Dr G. Marshman  West Timor – lessons for a dermatologist
Dr T. O’Brien  Dermatological anthropology
Dr M. Whitfeld  Skin cancer prevention and education: First Fijian Albinism workshop
Dr L. Romani  System review of the global prevalence of scabies and impetigo
Dr P. Kumarasinghe  Quiz - cases

1045-1200  “WHAT’S CAUGHT MY EYE” – AN UPDATE SESSION
Dr C. Duguid  Non melanoma skin cancers
A/Prof. J.W. Kelly  Melanoma
Dr J-A. See  Acne/roacea/hidradenitis suppurativa
Dr L. Warren  Immunobullous conditions/ genodermatoses
Dr J. Wayte  Eczema/urticarial disorders
A/Prof. S. Zagarella  Drug reactions

1330-1345  CONTINUING PROFESSIONAL DEVELOPMENT
Presenter: Dr A. Lewis
Convenor of the ACD CPD Committee

1345-1445  PLENARY SESSION 3
Prof. A. Yan
The year in review: Update on paediatric dermatology
Prof. A. Yan
Inpatient consultative paediatric dermatology

1445-1500  PRESENTATION OF AWARDS AND CLOSING REMARKS
### Tuesday 19 May 2015

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chairs</th>
<th>Panel Discussion</th>
</tr>
</thead>
<tbody>
<tr>
<td>0845–0945</td>
<td><strong>SESSION 8: INTRODUCTION TO SKIN CARE AND SKIN CARE PANEL</strong>&lt;br&gt;Chairs: Dr K. Armour and Dr A. Rudd</td>
<td>Should we sell skincare in our practices? Nutraceuticals</td>
<td>Panel discussion&lt;br&gt;Industry Input&lt;br&gt;Mr R. Parker, Rationale&lt;br&gt;Ms I. Ciavarra, Obagi Skin Care&lt;br&gt;Ms T. Vinson, Synergie&lt;br&gt;Panel discussion</td>
</tr>
<tr>
<td>0945–1030</td>
<td><strong>SESSION 9: FILLERS</strong>&lt;br&gt;Chairs: Dr M. Rich and Dr A. Lim</td>
<td>Skin boosters and Emervel range Pushing the boundaries: Radiesse injection beyond the face: Hyper dilution for neck and arm</td>
<td>Questions</td>
</tr>
<tr>
<td>1100–1215</td>
<td><strong>SESSION 9: FILLERS (CONTINUED)</strong>&lt;br&gt;Panel (international and local speakers): Fillers with suggested treatment guidelines&lt;br&gt;Upper face&lt;br&gt;Mid face&lt;br&gt;Lower face</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1215–1300</td>
<td><strong>SESSION 10: BOTULINUM TOXIN</strong>&lt;br&gt;Chairs: Dr L-M. Yap and Dr E. Dawes-Higgs</td>
<td>Combination use of filler and neurotoxin Hyperhidrosis</td>
<td>Panel&lt;br&gt;Dr T. Walker&lt;br&gt;Dr C. Martschin&lt;br&gt;Panel</td>
</tr>
<tr>
<td>1400–1445</td>
<td><strong>SESSION 10: BOTULINUM TOXIN (CONTINUED)</strong>&lt;br&gt;Chairs: Dr L-M. Yap and Dr E. Dawes-Higgs</td>
<td>Avoiding neurotoxin complications</td>
<td>Expert panel&lt;br&gt;Panel&lt;br&gt;Dr T. Walker&lt;br&gt;Dr C. Martschin&lt;br&gt;Panel</td>
</tr>
<tr>
<td>1445-1530</td>
<td><strong>SESSION 11: LASERS</strong>&lt;br&gt;Chairs: Dr D. Lim and Dr P. Bekhor</td>
<td>Dr E. Tanghetti Superficial fractional Picosecond with focus handpiece for rejuvenation Dr J. Green Short pulsed lasers</td>
<td>Questions</td>
</tr>
<tr>
<td>1600–1700</td>
<td><strong>SESSION 12: DEBATES</strong>&lt;br&gt;First debate: Cryolipolysis is now the preferred fat reduction modality for dermatology practices in Australia&lt;br&gt;Chairs: Dr B. Pruim and Dr D. Lanzer&lt;br&gt;Affirmative: Dr B. Pruim and A/Prof. Greg Goodman&lt;br&gt;Negative: Dr D. Lanzer and Dr M. Rich&lt;br&gt;Sum up and adjudication: Dr E. Tanghetti, with the help of audience&lt;br&gt;Second Debate: Are men worth the trouble?&lt;br&gt;Chairs: Dr C. McDonald and Dr E. Yiasemides&lt;br&gt;Affirmative: Dr B. Welsh and Dr B. Pruim&lt;br&gt;Negative: Dr C. McDonald and A/Prof. P. Foley&lt;br&gt;Overview of the differences between treating men and treating women with procedures, managing their expectations&lt;br&gt;Minor but annoying complaints&lt;br&gt;Chairs: Dr S. Richards and Dr V. Morgan&lt;br&gt;Seb Ks, sebaceous hyperplasia, skin tags, milia, intradermal naevi&lt;br&gt;Panels on smaller procedures&lt;br&gt;FWD, shave, snip biopsy, punch techniques, subcision, curette&lt;br&gt;Acne scarring</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The following posters will be displayed at the meeting:

1. Dr I. Abdel-Malek
   Use of adhesive retention tapes to anchor surface sutures in random pattern flaps: Designs, plans and options

2. Dr M. Abikhair
   Treatment refractory atopic dermatitis with ichthyosis vulgaris responding to Omalizumab

3. Dr S. Andrews
   Tele-derm national highlights: Eruptive xanthomas heralding type V hyperlipidaemia

4. Dr S. Andrews
   Tele-derm national highlights: Bullae on the lower legs of a 90-year-old woman - a diagnostic challenge

5. Dr S. Andrews
   Tele-derm national: Diagnostic highlights and management gems

6. Dr R. Anforth
   Factors influencing the development of cutaneous squamous cell carcinomas in patients on BRAF inhibitor therapy

7. Miss R. Ang
   The autoimmune bullous disease quality of life and treatment of autoimmune bullous disease quality of life questionnaires - trends and responsiveness

8. Miss R. Ang
   The treatment intensity scoring system and treatment adversity scoring system - two scoring systems for treatments used in autoimmune blistering diseases

9. Dr S. Arnold
   The Oxford University Hospital’s inpatient email advice line

10. Dr L. Byrom
    Undiagnosed severe neonatal ichthyosis: The role of genetic testing

11. Dr G. Carlos
    Bullous annular lichen planus in a patient on Pembrolizumab

12. Dr P. Chadha
    Secukinumab treatment leads to proteomic and transcriptional changes in psoriatic skin

13. Dr C. Chaptini
    Durable dermatology life quality index (DLQI) improvements in patients on biologics associated with psoriasis areas and severity index (PASI) score

14. Dr C. Chaptini
    Gross hepatomegaly secondary to AA amyloidosis in RDEB: An under-recognised complication

15. Dr H.M. Cheng
    Assessment of the optimal interval for digital dermoscopy monitoring for the evaluation of pigmented nail lesions

16. Dr H.M. Cheng
    Optical coherence tomography in the presurgical margin delineation of Mohs surgery in infiltrative BCC

17. Dr A. Chia
    Safety of TNF-? inhibitors in HIV patients

18. Dr Y.Z. Chiang
    Biochip immunofluorescence microscopy as a new diagnostic tool for autoimmune blistering skin diseases in Australia

19. Dr D. Choi
    Another chemotherapy reaction? Hyperpigmentation due to alkylating agents revisited

20. Dr M. Cicchiello
    Radiotherapy-induced eruptive keratoacanthomas of the face - a case of Ferguson-Smith disease responsive to acitretin therapy

21. Dr P. Clarke
    The proportion of the Australian population which develops skin cancer

22. Dr A. Collins
    Secukinumab 300mg demonstrates highest probability of efficacy than other biologics in psoriasis: indirect comparison

23. Dr V. Cox
    Review of the proposed pathogenic mechanisms underlying rosacea and possible clinical implications of vascular and inflammatory involvement

24. Dr G. Daley
    Lipohypertrophy after autologous fat transplantation for lip enhancement

25. Dr G. Daley, Ms K. Lee and Ms K. Jadirdar
    Glutathione S-transferase P1 Ile105Val polymorphism: phenotypic characteristics and melanoma risk

26. Dr B. Daniel
    An Australian perspective on skin of colour: results of a national survey

27. Dr D. Daniels
    Protecting the delicate skin of infants

28. Dr C. de Belilovsky
    Sunflower oleodistillate: A topical PPAR-? agonist developed for atopic dermatitis

29. Dr C. de Belilovsky
    Tolerance assessment of cosmetic products dedicated to baby’s skin: Innovative approaches using stinging test and infant epidermis model

30. Dr C. de Belilovsky
    Identification of specific markers for epidermal maturation in infancy leading to a new generation of baby skin care
Dr C. de Belilovsky
Avocado perseose, a biomimetic active ingredient for the protection and accompaniment of infants’ skin

Dr C. de Belilovsky
Anti-itching and barrier restoring effects of a Lipid-replenishing Balm on atopic dermatitis models

Dr K. Deen
Porphyria cutanea tarda masquerading as epidermolysis bullosa acquisita - a report of two cases

Dr L. Demediuk
Multifocal panniculitis due to Mycobacterium Ulcerans: An unusual presentation of an increasingly common disease

Mr H. Edwards
Advancement in calciphylaxis management: report of 3 cases

Mr L. Escudero Herra
Multi-country, cross-sectional study to determine patient-specific and general beliefs toward medication and their treatment adherence to selected systemic therapies in 6 chronic immune-mediated inflammatory diseases (ALIGN)

Mr L. Escudero Herra
Safety and efficacy of Adalimumab in patients with moderate to severe hidradenitis suppurativa: results from first 12 weeks of PIONEER I, a phase 3, randomized, placebo-controlled trial

Mr L. Escudero Herra
Efficacy and safety of Adalimumab in patients with moderate to severe hidradenitis suppurativa: results from PIONEER II, a phase 3 randomised placebo-controlled trial

Dr B. Fergie
Perforating paraneoplastic granuloma annulare of the hands and feet - two cases reported

A/Prof. P. Foley
Secukinumab shows efficacy in subjects with and without previous exposure to biologic psoriasis therapy: Subanalysis from the phase 3 FIXTURE study

A/Prof. P. Foley
Secukinumab treatment sustains patient-reported outcome benefits through 1 year

A/Prof. P. Foley
Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: A Phase 3 randomized trial

A/Prof. P. Foley
Long-term safety and tolerability of Apremilast in patients with psoriasis: pooled safety analysis of the ESTEEM 1 and 2 trials

Dr S. Gabizon
Statins reduce the risk of melanoma: Truth or myth?

Dr D. Gaffney
Clear cell renal carcinoma presenting as a skin papule on the nose: A rare presentation with variable prognosis

Dr A. Gin
Trichodyplasia spinulosa

A/Prof. G. Goodman
ReCell - an automated kit for the treatment of hypopigmentation

Dr K. Greive
Topical products to relieve and restore sun-exposed skin

Dr A. Harris
Multiple cutaneous reticulohistiocytomas successfully treated with topical PUVA combined with intralesional injections of triamcinolone acetonide

Dr A. Harris
The epidermolysis bullosa disease activity and scarring index (EBDASI) mobile phone application

Dr A. Harris
An analysis of the rurality of patients with epidermolysis bullosa in Australia

Dr A. Harris
Combining microneedling and triamcinolone - a novel way to increase the tolerability of intralesional corticosteroid delivery in children with alopecia areata

Dr A. Harris
Skin needling as a treatment for acne scarring: An up to date review of the literature

Dr C. Higgins
Psoriasis severity is influenced by nutritional intake: Results of a dietary and lifestyle questionnaire in Victorian psoriasis patients

Miss L. Illingworth
Risk factors for melanoma in Tasmania: Can targeted screening be achieved?

Dr A. Ingham
Nasal bridge skin necrosis following regular use of CPAP ventilation pressure mask

Miss S. Jain
Characterising severity and responsiveness of a new outcome measure for epidermolysis bullosa - the epidermolysis bullosa disease activity and scarring index

Dr H. Jones
Validation of the physician global assessment and BSA composite tool as an alternative to the PASI for psoriasis assessments

Dr C. Kalai
Cross-reactivity between multiple classes of topical corticosteroids in a treatment-resistant groin dermatitis

Dr M. Khalesi
Comparison of P53, COX-2, PTCH1 and Ki67 gene expression patterns between basal cell carcinomas at different anatomical sites and of different subtypes
61. Dr B. Kim
How sunSmart are Australian women?

62. Dr J. Kim
Cyclical inguinal keratoderma: A new clinical entity?

63. Dr J. Kim
Dystrophic calcinosis cutis in the setting of a myositis/scleroderma overlap syndrome

64. Dr J. Kim
Cutaneous alternaria infection of the hand in an immunocompromised patient

65. Dr J. Kim
Facial follicular porokeratosis: Two cases from Western Australia

66. Dr M. Kim
Squamous cell carcinoma in recessive dystrophic epidermolysis bullosa has high metastasis potential due to a permissive tumour microenvironment

67. Dr A. Lalji
Diabetes mellitus and necrobiosis lipoidica

68. Dr Q. Le
A single-institution experience of paediatric melanoma in Victoria, Australia

69. Dr A. Lee
Fractional carbon dioxide laser in recalcitrant vulval lichen sclerosus

70. Dr P.A. Lee
Cardiac medications in dermatology- a review of the literature

71. Dr N. Linklater
Case of atypical Sweet’s syndrome

72. Dr N. Linklater
Case report of a full thickness burn following the use of a Chlorhexidine patch

73. Dr N. Linklater
Case of Toxic epidermal necrolysis following a dogbite

74. Dr N. Linklater
Melanoma - The Royal Hobart Hospital experience

75. Dr H. Lolatgis
Pigmented purpuric eruption following the lines of blaschko in a child

76. Dr J. Ma
Tiger, tiger: A dermatomal distribution of AGEP

77. Dr N. Maher
Disseminated mycobacterium chelonae infection

78. Dr C. Maiolo
Complications of Hydroxyurea Therapy: Dermatology the key to diagnosis

79. Miss Nikki McKevitt
Improvement in nail psoriasis in the open-label extension of a phase-2 trial of ixekizumab in patients with moderate-to-severe plaque psoriasis

80. Miss N. McKevitt
Effects of ixekizumab treatment on quality of life during 48 weeks of open-label treatment in a phase-2 trial in psoriasis

81. Miss N. McKevitt
Impact of ixekizumab on blood neutrophil levels and the incidence of infections caused by Candida albicans or Staphylococcus aureus

82. Dr R. McQualter
Three IL-17 ligands contribute to psoriasis: Blockade of IL-17RA signalling with brodalumab

83. Dr R. McQualter
Improvement of psoriasis in subjects with and without psoriatic arthritis: subanalysis of a brodalumab (AMG 827) phase 2 study for moderate to severe plaque psoriasis (PsO)

84. Dr R. McQualter
Maintenance of clinical response with long-term brodalumab (AMG 827) therapy for psoriasis: week 144 results from an open-label extension study

85. Dr R. Meani
Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor Vismodegib (GDC-0449)

86. Dr R. Meani
Review of the Victorian Melanoma Service - a statewide multidisciplinary melanoma referral centre

87. Dr F. Menz
A retrospective study of psoriasis patients treated with long contact dithranol in a dermatology day unit

88. Dr R. Minocha
Systemic and erythrodermic reaction following repeated exposure to bites from the common bed bug, Cimex lectularius

89. Dr R. Minocha
Interstitial granulomatous dermatitis presenting with scleroderma-like changes associated with dystrophic calcification and a review of the literature

90. Dr R. Minocha
Necrobiotic xanthogranuloma: A report of two unique cases

91. Dr R. Minocha
The progressive clinical course of Cimicosis; the dermatological affects from the common bed bug, Cimex lectularius

92. Dr E. Mooney
Chromonychia: A brief review

93. Dr E. Mooney
Kaposi’s sarcoma

94. Dr D. Norris
Treatment of granuloma faciale with intralesional Kenacort-A 10 and 5-Fluourouracil combination therapy
95. Dr D. Norris
Reduced levels of self-reported psychological distress associated with multidisciplinary melanoma clinic attendance

96. Dr D. Norris
Dermatology life quality index in the Australian psoriasis population

97. Dr A. O'Connor
Stewart-Bluefarb syndrome secondary to arteriovenous malformations and acquired non-traumatic arteriovenous fistula: Report of five cases and a review of literature

98. Dr N. Ong
My patient has loss of MSH2 and 6 in their sebaceous adenoma; do they have Muir Torre syndrome?

99. Dr N. Ong
Molecular profiles of reticular and globular naevus patterns: A pilot study

100. Dr N. Ong
A clinical audit of high-cost approved drugs in dermatology: 2003 - 2013

101. Dr G. Parham
Understanding longitudinal melanonychia

102. Dr G. Parham
Linear erythematous cutaneous adverse reaction during intravenous Iloprost administration

103. Dr P. Peters
Adult Blaschkitis: An unusual unilateral presentation

104. Dr L. Pitney
Intermittent combined low dose UVA1/narrow band UVB therapy for cutaneous T-Cell lymphoma/Sezary syndrome: Report of a case and discussion of its implications

105. Dr M. Pitney
Scleredema of Buschke: A report of associated acute bowel obstruction and review of systemic complications

106. Dr F. Poon
Severe erosive lichen planus of the penis treated effectively with oral acitretin

107. Dr F. Poon
Return of the great masquerader: A review of the resurgence of Syphilis in Australia through clinical vignettes

108. Dr F. Poon
The impact of an outpatients’ online handover tool: Timely follow-up and safe patient care in the Dermatology Department at The Royal Melbourne Hospital

109. Dr H. Rajgopal Bala
Two cases of acute amoxycillin induced follicular pustulosis

110. Dr J. Raymond
Congenital Becker’s naevus - a case report and literature review

111. Dr J. Read
Familial melanoma and links with other cancers

112. Dr S. Richter
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 52-week results of the ESTEEM 2 trial

113. Dr S. Richter
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with nail, scalp, and palmoplantar psoriasis: 52-week ESTEEM 2 study results

114. Ms L. Romani
Scabies and impetigo prevalence and risk factors in Fiji: A national survey

115. Dr A. Ross
Cognitive function in patients with psoriasis while on biologic therapies: Pilot study

116. Dr C. Rowe
Psychological impact of chronic childhood skin disease on caregivers and families: A review

117. Dr C. Rowe
Immune cell infiltrate subtypes inform on melanoma survival in stage Ib and II melanomas

118. Dr A. Sahebian
A review on uncommon malignancies associated with dermatomyositis

119. Dr A. Sahebian
Prevalence of actinic keratosis and the risk factors for skin cancer in lung transplant recipients in Queensland, Australia

120. Dr R. Saunderson
Palisading neutrophilic granulomatous dermatitis secondary to a novel anti-diabetic medication, dapagliflozin

121. Dr R. Saunderson
Antibiotic therapy for Staphylococcus aureus colonised vascular catheter tips and the occurrence of bacteraemia - implications for hospital policy

122. Mr A. Shahnam
Sun protection practices of undergraduate university students

123. Dr S. Shen
The unique clinical behaviour of desmoplastic melanoma

124. A/Prof. S. Shumack
Secukinumab shows efficacy in subjects with and without previous exposure to biologic psoriasis therapy: Subanalysis from the phase 3 FIXTURE study

125. Prof. R. Sinclair
Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response

126. Dr S. Sinnya
Use of mobile app for patient information in solid organ transplantation - minimising gaps in patient education
127. Dr S. Sinnya
Emergence of squamous cell carcinomas post Nilotinib therapy for chronic myelogenous leukemia - a rare adverse effect of a second generation tyrosine kinase inhibitor

128. Dr E. Smith
Cutaneous melioidosis

129. Dr S. Smith
Assessment of the attitude of dermatologists to the use of topical corticosteroids in paediatric atopic dermatitis

130. Dr S. Smith
Assessment of attitudes towards sun-protective behaviour in Australia: A cross-sectional study

131. Dr S. Smith
Trends in thickness and survival of primary in situ and invasive cutaneous melanoma in Victoria, Australia

132. Dr S. Smith
Prognosis of melanoma of unknown primary

133. Dr P. Sobarun
Porphyria cutanea tarda in a patient on haemodialysis and iron deficiency

134. Dr S. Sokolovska
Outcomes of pemphigus treatments at the Royal Melbourne Hospital over 5 years on immunosuppressive therapies used over this time: a retrospective analysis

135. Dr S. Sokolovska
Treatment of Behcets disease with subcutaneous testosterone: A case report

136. Dr L. Spelman
Secukinumab treatment provides fast relief from patient-reported psoriasis burden

137. Dr L. Spelman
Secukinumab shows efficacy regardless of baseline disease severity in subjects with moderate-to-severe plaque psoriasis: A pooled analysis from four phase 3 studies

138. Dr S. Strathie Page
Mycophenolic acid: Applications in dermatology

139. Dr S. Strathie Page
Ulcerated rapidly involving congenital hemangiomas: A case series

140. Dr S. Strathie Page
Acrodermatitis dysmetabolica

141. Dr S. Strathie Page
Wiskott-Aldrich syndrome in an Australian population

142. Dr A. Tan
Non-bullous lichen planus pemphigoides likely induced by venlafaxine

143. Dr A. Tan
A typical presentation of hypomelanosis of Ito - a rare pigmentary chromosomal mosaicism

144. Dr A. Tan
Allergic contact dermatitis and systemic symptoms from wearing the new navy blue South Australian police uniform

145. Dr J-M. Tan
Histopathological features after topical black salve application

146. Dr J-M. Tan
Eosinophilic folliculitis in a patient receiving chemotherapy for chronic lymphocytic leukaemia - case report and review of the literature

147. Dr J-M. Tan
Localised neutrophilic eccrine hidradenitis secondary to 5-Fluorouracil infusion for mixed adenoneuroendocrine tumour

148. Dr J-M. Tan
A case of carbimazole-induced lichenoid drug eruption

149. Dr W.P. Tan
The perialar cresenteric advancement flap - a versatile flap for repair of nasal dorsum and upper cutaneous lip defects

150. Dr C. Thomas
A case of mistaken identity: unilateral erythema elevatum diutinum associated with IgA paraproteinaemia

151. Dr C. Thomas
“The physician who knows syphilis knows medicine”: Secondary syphilis masquerading as pityriasis rosea

152. Dr C. Thomas
MEK-Inhibitor induced compound skin toxicity with oedema in metastatic malignant melanoma: A case series

153. Dr B. Thompson
Skin infection secondary to Purpureocillium lilacinum associated with a spider bite in an immunocompetent patient - a rare case report

154. Dr A. Thornton
Background exercise and creatine kinase levels in acne patients commencing isotretinoin

155. Dr S. Tizi
Oculocutaneous Tyrosinaemia - a case report of a late diagnosis at age 17

156. Dr N. Torkamani
Cells expressing epidermal stem cell markers are exclusively localised at the distal end of the arrector pili muscle in non-glabrous skin

157. Dr E. Trowbridge
Congenital cutaneous candidiasis: A rare neonatal disease

158. Dr L. von Schuckmann
Vitamin D receptor polymorphisms and keratinocyte skin cancers: A cohort study and meta-analysis

159. Dr L. von Schuckmann
Body hair density and risk of keratinocyte skin cancer in Australian adults
160. Dr A. Wallett
Radiation therapy induced neuro-Sweet’s disease in a patient with oral squamous cell carcinoma

161. Dr G. Whiting
General practice registrars’ clinical experience of dermatology during training: A cross-sectional analysis from the registrar clinical encounters in training study

162. Miss A. Wijayanti
Validity, reliability, responsiveness and minimal clinically important difference of the bullous pemphigoid disease area index (BPDAI)

163. Dr G. Winkler
The use of biologic agents for hidradenitis suppurativa by Australian dermatologists

164. Dr C. Wong
Teledermatology: A one year experience from a Victorian tertiary hospital.

165. Dr A. Wylie
Secukinumab shows sustained response in subjects with moderate-to-severe plaque psoriasis: A subanalysis of the ERASURE phase 3 study

166. Dr C. Xie
Chronic granulomatous disease and lupus erythematosus

167. Dr C. Xie
Scalp melanoma has a distinct clinical presentation and aggressive histologic features

168. Dr B. Yau
Cutaneous SCC with dermal lymphatic spread: When surgery is not enough

169. Dr C. Zhao
Telogen effluvium and Beau’s lines induced by azathioprine: A case report

170. Dr C. Zhao
Severe ingenol mebutate skin reaction while on methotrexate: A case series and proposal of pathogenesis

171. Dr C. Zhao
Chlorophyll-induced pseudoporphyria with ongoing photosensitivity after cessation - a case series of 5 patients

172. Dr C. Zhao
Assessing skin diseases in patients with pigmented skin - A grey area

173. Dr C. Zhao
Recording of dermatology consults in discharge summaries: An analysis of 218 consults

174. Dr C. Zhao
A prospective comparison study of four outcome measures for atopic dermatitis
The following events have been organised for delegates and accompanying persons. All prices quoted include GST. Please indicate your intention to attend the social functions on the registration form.

### Saturday 16 May 2015

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1900-2400</td>
<td>TASTE SA: CONFERENCE DINNER, PANORAMA BALLROOM, ACC</td>
</tr>
</tbody>
</table>

Come and join us at the new-look conference dinner. Less formal than in previous years, but still giving everyone an opportunity to enjoy good conversation, music and great food! A variety of tastes and flavours from around South Australia will be on offer, presented in a fun, novel way. Set in the new Panorama Ballroom of the recently-extended Adelaide Convention Centre, “Taste SA” will offer beautiful views of Adelaide’s latest additions to the map, aligned along the River Torrens. Enjoy what the state has to offer, along with cool jazz and the company of friends and colleagues.

Music by the well-known Adelaide jazz band, Black Fedora, [http://blackfedora.info](http://blackfedora.info).

Cost: For all delegates who are fully registered, the cost is included in the ASM registration fee. Please note dinner cost included in the registration fee is not transferable.

For partners of above and others, the fee is: $165.00

### Sunday 17 May 2015

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1830-1930</td>
<td>GRADUATION ORATION AND CONFERRING OF DIPLOMAS AND AWARDS, HALL L, ACC</td>
</tr>
</tbody>
</table>

John Reid Orator: Dr Peter Goldsworthy, AM Australian writer and medical practitioner

Light refreshments will be available for graduands and their guests following the ceremony.

### Monday 18 May 2015

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1800-2000</td>
<td>MEN'S AND LADIES TENNIS TOURNAMENT</td>
</tr>
</tbody>
</table>

Venue: Next Generation Health and Racquet Club
War Memorial Drive
NORTH ADELAIDE
T 08 8110 7777

Cost: $30.00 per person

### Tuesday 19 May 2015

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>0930-1130</td>
<td>PRIVATE TOUR OF ADELAIDE CENTRAL MARKET AND BREAKFAST</td>
</tr>
</tbody>
</table>

Since 1869, the Central Market has been the jewel in the crown of South Australian Tourism experiences, a haven of premium food and wine products, and second home to chefs and food lovers. The tour is a sensory and interactive gourmet walking tour with a local food expert. Participants enjoy a range of delicious samples that represent the multicultural community of South Australia and the clean and green produce harvested from our farms and oceans.

Cost: $80.00 per person

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1230</td>
<td>GOLF</td>
</tr>
</tbody>
</table>

Venue: Royal Adelaide Golf Club
328 Tapleys Hill Road
SEATON
T 08 8356 5511

Tee off: 1300

Cost: $120.00 per person (includes light lunch and drinks afterwards) (maximum 16 people)
ACCOMMODATION

The College has appointed as accommodation brokers for College’s meeting:

Info Salons Australia Pty Ltd
PO Box K1385
HAYMARKET NSW 1240
T  +61 2 9280 1295
F  +61 2 9211 7470
E  dermatology@infosalons.com.au

College has selected a range of hotels and apartments in Adelaide. Info Salons has block booked accommodation at all these venues. This service is free for delegates.


Bookings can be made through the College website or on the accompanying accommodation form.

ACKNOWLEDGMENTS

The Australasian College of Dermatologists kindly acknowledges the generous support of the following sponsors in assisting with the Annual Scientific Meeting:

Platinum Sponsor

\[ \text{Novartis} \]

Gold Sponsors

\[ \text{Lilly} \]
\[ \text{JANSSEN-CILAG} \]

Others

\[ \text{Cutera} \]
\[ \text{Cynosure} \]
\[ \text{GALDERMA} \]
\[ \text{La Roche-Posay} \]
\[ \text{LEO} \]
\[ \text{Menarini} \]
Please note that Annual Scientific Meeting and the Trade Exhibition are managed on behalf of the College by ACD Educational Enterprises Pty Ltd as Trustee for the ACD Educational Enterprises Unit Trust.

ACD Educational Enterprises Pty Ltd as Trustee for the ACD Educational Enterprises Unit Trust
PO Box 3785, RHODES NSW 2138, Australia

T +61 2 8765 0242
or 1300 361 821 (within Australia only)
F +61 2 9736 2194
E admin@dermcoll.edu.au
W http://www.dermcoll.edu.au